---
title: "Nomura Cuts HENGRUI PHARMA  TP to HKD82.18, Lowers FY2026 Revenue and Profit Forecasts"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293875263.md"
description: "Nomura maintained a Buy rating on Hengrui Pharma but lowered its target price from HKD87.49 to HKD82.18 and cut FY2026 revenue and profit forecasts by 7.8% and 18.4%, respectively, due to slower-than-expected out-licensing revenue recognition. The broker expects Q2 revenue to rise 1% YoY to RMB8.6 billion, with net profit up 11% to a record RMB2.9 billion."
datetime: "2026-07-27T03:29:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293875263.md)
  - [en](https://longbridge.com/en/news/293875263.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293875263.md)
generator: "portal-rs"
---

# Nomura Cuts HENGRUI PHARMA  TP to HKD82.18, Lowers FY2026 Revenue and Profit Forecasts

Nomura released a report expecting HENGRUI PHARMA (01276.HK) +0.900 (+1.589%) Short selling $44.81M; Ratio 36.976% 's 2Q revenue to rise 1% YoY to RMB8.6 billion. In terms of margins, gross margin is forecast to decline to 85.9%, down 1.1 ppts YoY, while operating margin is expected to increase to 31.2%, up 0.5 ppts YoY, mainly due to lower selling expenses. Together with non-recurring gains, including fair value gains from the valuation increase of Hengrui's new overseas company, 2Q attributable net profit is expected to rise 11% YoY to a record high of RMB2.9 billion.

For 2H, the broker estimated HENGRUI PHARMA's revenue to increase 10.2% YoY to RMB17.5 billion, while net profit is expected to reach RMB4 billion, up 22% YoY. The Buy rating was maintained, while the TP was lowered from HKD87.49 to HKD82.18. FY2026 revenue and net profit forecasts were cut by 7.8% and 18.4%, respectively, to reflect slower-than-expected recognition progress of out-licensing revenue. (ha/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-07-24 16:25.)

### Related Stocks

- [01276.HK](https://longbridge.com/en/quote/01276.HK.md)
- [600276.CN](https://longbridge.com/en/quote/600276.CN.md)
- [8604.JP](https://longbridge.com/en/quote/8604.JP.md)
- [NMR.US](https://longbridge.com/en/quote/NMR.US.md)

## Related News & Research

- [HENGRUI PHARMA  1H26 Net Profit Rises 0.3% YoY to RMB4.465 Billion; Shares Now Down Over 7%](https://longbridge.com/en/news/296422700.md)
- [Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth | KLRA Stock News](https://longbridge.com/en/news/283635919.md)
- [Chinese Pharma Companies Plan Hong Kong Listings](https://longbridge.com/en/news/297979501.md)
- [REG - Union Jack Oil PLC Reabold Resources - Statement regarding Reabold offer](https://longbridge.com/en/news/298036801.md)
- [China Resources Pharma unit KPC wins registration to issue RMB 1 billion in medium-term notes](https://longbridge.com/en/news/297630970.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**